Buy Ranbaxy above Rs 290: Sanjeev Agarwal

Sanjeev Agarwal, CEO of Dynamix Research & Capital Management told CNBC-TV18, " Ranbaxy Laboratories is trying to make a base. If it is able to hold above Rs 287-288 for that matter it should rise at least up to Rs 325-330. Overall Ranbaxy has seen the worst already and the downside seems to be very low. However, above Rs 290 definitely it is a buy."

On August 07, 2013 Ranbaxy Laboratories closed at Rs 281.90, up Rs 12.35, or 4.58 percent. It has touched an intraday high of Rs 286.40 and an intraday low of Rs 261.50.

The share touched its 52-week high Rs 578.30 and 52-week low Rs 253.95 on 04 September, 2012 and 02 August, 2013, respectively. Currently, it is trading 51.25 percent below its 52-week high and 11.01 percent above its 52-week low. Market capitalisation stands at Rs 11,927.22 crore.

Anda sedang membaca artikel tentang

Buy Ranbaxy above Rs 290: Sanjeev Agarwal

Dengan url

https://untukkesehatanda.blogspot.com/2013/08/buy-ranbaxy-above-rs-290-sanjeev-agarwal.html?m=0

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Buy Ranbaxy above Rs 290: Sanjeev Agarwal

namun jangan lupa untuk meletakkan link

Buy Ranbaxy above Rs 290: Sanjeev Agarwal

sebagai sumbernya